Utility of 18 F-FDG PET/CT in pre-surgical risk stratification of patients with breast cancer

Hell J Nucl Med. 2019 Sep-Dec;22(3):165-171. doi: 10.1967/s002449911051. Epub 2019 Oct 7.

Abstract

Objective: To determine the correlation between fluorine-18-fluorodeoxyglucose (18F-FDG) uptake values and clinicopathological prognostic markers using preoperative 18F-FDG positron emission tomography/computed tomography (PET/CT) in primary breast cancer (BC).

Subjects and methods: One hundred and twelve patients with primary BC were studied prospectively. Pretreatment 18F-FDG PET/CT was performed. Maximum standardized uptake values (SUVmax) were compared with various clinicopathological variables.

Results: In a univariate analysis, SUVmax correlated well with the following prognostic variables: T stage, absence of progesterone receptor (PR), absence of estrogen receptor (ER), triple negative lesions (ER/PR and Her 2 negative) and high histologic grade. Metastatic lesions and ductal lesions had higher SUVmax than lobular carcinoma. No significant correlation was found between SUVmax,and human epidermal growth factor receptor 2 (Her-2) statusor perineural and lymphovascular invasion. Multivariate analyses showed that breast density, tumor size and PR negativity were significantly correlated with SUVmax (P=0.046 and 0.009, respectively).

Conclusion: The pre-treatment tumor SUVmax could be utilized as an independent imaging biomarker of the tumor aggressiveness and poor prognosis. Risk stratification based on this index could play a pivotal role in alteration of treatment planning, such as neoadjuvant chemotherapy (precision oncology).

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Breast Neoplasms / surgery*
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Neoplasm Grading
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Positron Emission Tomography Computed Tomography*
  • Preoperative Period*
  • Receptors, Estrogen / metabolism
  • Receptors, Progesterone / metabolism
  • Risk Assessment

Substances

  • Receptors, Estrogen
  • Receptors, Progesterone
  • Fluorodeoxyglucose F18